Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (NASDAQ: TWST) is a synthetic biology and biotechnology company whose news flow reflects its focus on synthetic DNA tools, silicon-based DNA synthesis and research-enabling technologies. Company announcements frequently describe Twist as a mid-cap growth and value biotech company serving customers in medicine, agriculture, industrial chemicals and defense, where its DNA-based products support research and development programs.
On this page, readers can follow TWST news related to product launches, collaborations, financial updates and corporate developments. Recent press releases have highlighted the launch of research-grade plasmid DNA preps for nucleic acid therapeutics research, including animal origin-free and transfection-grade options with specific quality attributes and target yields. Other announcements cover expanded collaborations, such as the Trinity Freestyle Fast Hybridization workflow developed with Element Biosciences for the AVITI sequencing platforms.
Investors and researchers can also track earnings-related news, including preliminary revenue updates, quarterly and full-year financial results, and associated conference calls and webcasts. Corporate governance and compensation updates, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), appear in Twist’s news stream as well.
In addition, Twist publishes news on biosecurity and policy engagement, including participation in a Science paper examining biosecurity screening practices in AI-assisted protein design. Conference presentations at major healthcare and life science events are also regularly announced. For anyone following TWST stock or the evolution of synthetic DNA technologies, this news page provides a centralized view of Twist Bioscience’s public communications and key milestones.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust will present at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, at 3:20 p.m. Eastern Time. The presentation will be available for live streaming on the company's investor relations website, with a replay accessible for 30 days post-event. Twist is a leader in synthetic biology, utilizing a proprietary silicon-based DNA synthesis platform to create a wide array of synthetic DNA products for various sectors, including healthcare and agriculture.
Summary not available.
Twist Bioscience Corporation (NASDAQ: TWST) will announce its fiscal 2021 fourth quarter and full-year financial results on November 22, 2021, before the market opens. A conference call for analysts and investors will follow at 8:00 a.m. Eastern Time, providing insights into the financial outcomes and business updates. Financial results will be accessible on the company’s website prior to the call. Twist is recognized for its innovative DNA synthesis platform, manufacturing various synthetic DNA-based products for multiple industries including healthcare and agriculture.
Twist Bioscience has launched Exome 2.0, boasting the most comprehensive coverage of protein-coding and noncoding regions of the genome. This innovative product enhances sequencing efficiency with lower costs and best-in-class performance, offering improved uniformity and a higher on-target rate. The Exome 2.0 is designed for applications addressing rare diseases and inherited disorders. The release underscores the company's commitment to supporting genomics researchers with customizable and efficient solutions.
Twist Bioscience has announced a collaboration with the Broad Institute to distribute the Twist Alliance Clinical Research Exome, a next-generation sequencing panel targeting genes related to cancer and inherited diseases. Designed using validated clinical data, this panel enhances sequencing efficiency and supports the Broad's efforts in processing over 250,000 samples. It will be available mid-October, combining various genomic regions to facilitate deeper insights into genetic variants for therapeutic applications.
Twist Bioscience Corporation (NASDAQ: TWST) has appointed Steffen Hellmold as senior vice president of business development for data storage. This newly created position aims to bolster the company's commercialization efforts in DNA data storage solutions, which are anticipated to be significant in the market. Hellmold, previously of Western Digital, brings extensive experience in storage innovation. CEO Emily M. Leproust emphasized that his appointment will help establish critical relationships and define the commercialization strategy as they advance in this innovative field.
Twist Bioscience Corporation (TWST) and Centogene N.V. (CNTG) have partnered to develop custom assay kits targeting the diagnosis of rare diseases. This collaboration aims to enhance genetic testing accessibility for patients, ultimately improving understanding and treatment of rare conditions. Although no financial details were disclosed, the partnership seeks to utilize Centogene's extensive Bio/Databank and Twist's DNA synthesis technologies. The initiative is part of Centogene's goal to drive insights and potentially cure up to 100 rare diseases within the next decade.
Twist Bioscience Corporation (NASDAQ: TWST) has expanded its product offerings with the launch of the Twist Alliance Pan-Cancer Methylation Panel, designed for extensive cancer research applications. This panel, developed in collaboration with the Regeneron Genetics Center, covers 31 cancer types, optimizing sequencing costs and analysis complexity. Validation of the panel shows its effectiveness in differentiating cancer from non-malignant tissues. Twist's Alliance Panels aim to enhance research capabilities by providing expert-designed, clinically validated tools.
Twist Bioscience Corporation (NASDAQ: TWST) has appointed Dennis Cho as senior vice president, general counsel, and chief ethics and compliance officer. With over 25 years of corporate legal experience in the biotech industry, Cho aims to support Twist’s growth across synthetic biology and genomics. Previously, he held significant roles at CytomX Therapeutics and Seattle Genetics. CEO Emily Leproust expressed confidence in Cho's expertise to guide the company’s strategic initiatives. Twist strives to revolutionize DNA synthesis and applications across various industries, including healthcare and agriculture.
Twist Bioscience Corporation (TWST) announced promising results for its antibody candidate TB202-3, showing potent binding to various SARS-CoV-2 variants, including the E484K, N501Y, and D614G mutations. Conducted by the Coronavirus Immunotherapy Consortium, the analysis demonstrated that TB202-3 completely obstructs the virus's binding to human ACE2, indicating its potential effectiveness against COVID-19. The company is also advancing a new antibody, TB339-031, targeting additional variants. These findings underscore the antibody's broad applicability amidst evolving viral strains.